Table 5 |
||||||||||
|
Urine Clinical Safety Markers |
||||||||||
| 300 mg |
600 mg |
|||||||||
|
|
||||||||||
| Week |
0 |
1 |
3 |
8 |
11 |
0 |
1 |
3 |
8 |
11 |
|
|
||||||||||
| Glucose |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Ketones |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Blood |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Protein |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Nitrite |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Bilirubin |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Leukocytes |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
0 ± 0 |
| Specific Gravity |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.01 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
1.02 ± 0.01 |
| pH |
5.5 ± 0.76 |
5.6 ± 0.58 |
5.9 ± 0.90 |
5.4 ± 0.68 |
5.3 ± 0.53 |
5.8 ± 1.13 |
5.8 ± 1.13 |
5.8 ± 1.13 |
5.8 ± 1.13 |
5.8 ± 1.13 |
| Urobilinogen (E.U./dl) |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
0.2 ± 0.0 |
|
|
||||||||||
|
No significant differences were observed (p > 0.05). A zero reading indicates that there were no traceable amounts of markers present. Readings that were above a zero reading indicated a trace amount and are otherwise indicated by numbers 1, 2, and 3. |
||||||||||
|
Rohle et al. Journal of the International Society of Sports Nutrition 2007 4:13 doi:10.1186/1550-2783-4-13 |
||||||||||
